Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus-associated tuberculosis.
Charlotte SchutzMaxwell ChirehwaDavid BarrAmy WardSaskia JanssenRosie BurtonRobert J WilkinsonMuki SheyLubbe WiesnerPaolo DentiHelen McIlleronGary MaartensGraeme MeintjesPublished in: British journal of clinical pharmacology (2020)
Mortality in hospitalized HIV-TB patients was high. Early anti-TB drug exposure was similar to outpatients and not lower in inpatients who died. Rifampicin and isoniazid Cmax were suboptimal in 61% and 39% of inpatients and rifampicin exposure was higher in patients with high lactate. Treatment strategies need to be optimized to improve survival.
Keyphrases
- mycobacterium tuberculosis
- human immunodeficiency virus
- antiretroviral therapy
- hepatitis c virus
- pulmonary tuberculosis
- hiv infected
- hiv aids
- end stage renal disease
- hiv positive
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- cardiovascular events
- adverse drug
- peritoneal dialysis
- cardiovascular disease
- free survival
- south africa
- patient reported